Article

Advanced PCa treatment delays pain progression

Data from a phase III study have linked the advanced prostate cancer drug abiraterone acetate (ZYTIGA) to delayed pain progression and functional decline in a certain subset of advanced prostate cancer patients.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Sarah Razavi, MD, answers a question during a Zoom video interview
Sarah Razavi, MD, outlines strategies for mitigate surgeon discomfort during URS
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Can ctDNA detect molecular residual disease in NMIBC?
Kevin T. McVary, MD, FACS, answers a question during a Zoom video interview
Expert discusses setting realistic expectations for Rezum for BPH
1 expert is featured in this series.
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
Nicolette G. Payne, MD, answers a question during a Zoom video interview
Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists
Andrea Pezzella, MD, URPS, FACOG, answers a question during a Zoom video interview
Sacral neuromodulation device empowers patients with greater UUI control
Howard Goldman, MD, on his experience with the Glean Urodynamics System
Howard Goldman, MD, on his experience with the Glean Urodynamics System
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Study: Women with SCI are more likely to use indwelling catheters
Related Content
Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation
July 22nd 2025

Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

Hannah Clarke
The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.
Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr_Microbe - stock.adobe.com
July 21st 2025

Darolutamide plus ADT approved in EU for mHSPC

Hannah Clarke
This approval enables the use of darolutamide plus ADT with or without chemotherapy.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
Experts urge FDA to remove black box warning on low-dose vaginal estrogen
July 18th 2025

Experts urge FDA to remove black box warning on low-dose vaginal estrogen

Hannah Clarke
In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
July 18th 2025

Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

Hannah Clarke
In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.
© 2025 MJH Life Sciences

All rights reserved.